Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1997
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N03AG06
|
| gptkbp:CASNumber |
115103-54-3
|
| gptkbp:chemicalFormula |
C20H25NO2S
|
| gptkbp:contraindication |
hypersensitivity to tiagabine
|
| gptkbp:eliminationHalfLife |
7-9 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:genericName |
gptkb:tiagabine
|
| https://www.w3.org/2000/01/rdf-schema#label |
Gabitril
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Cephalon
|
| gptkbp:mechanismOfAction |
GABA reuptake inhibitor
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
96%
|
| gptkbp:riskFactor |
may increase risk of seizures in non-epileptic patients
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
confusion
nausea dizziness fatigue tremor |
| gptkbp:usedFor |
epilepsy
partial seizures |
| gptkbp:bfsParent |
gptkb:tiagabine
|
| gptkbp:bfsLayer |
7
|